Lomax M E, Barnes D M, Gilchrist R, Picksley S M, Varley J M, Camplejohn R S
Richard Dimbleby Department of Cancer Research, UMDS, St. Thomas' Hospital, London, UK.
Oncogene. 1997 Apr 17;14(15):1869-74. doi: 10.1038/sj.onc.1201133.
Previous investigations of a Li - Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene. In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient. The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene. A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was confirmed by sequencing of genomic DNA. This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain. This mutation results in a protein which still retains partial transactivational activity in the FASAY. The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.
先前对一个类似李-弗劳梅尼综合征的家族(巴恩斯等人,1992年)的研究表明,先证者及其母亲在肿瘤组织以及远离肿瘤部位的正常组织中,p53蛋白水平均升高,尽管在p53基因中未发现突变。在本研究中,采用了两种最近描述的p53功能检测方法,一种凋亡检测法和酵母中分离等位基因的功能检测法(FASAY),来研究该患者p53的功能活性。凋亡检测结果表明该患者存在p53功能缺陷,而FASAY结果提示这种缺陷实际上是p53基因的种系突变。最初在cDNA中发现了密码子337的点突变,该突变导致精氨酸被半胱氨酸取代的氨基酸替换,随后通过基因组DNA测序得以证实。这是一种不寻常的突变,因为它位于p53的寡聚化结构域,而大多数p53突变位于核心DNA结合结构域。这种突变产生的一种蛋白质在FASAY中仍保留部分反式激活活性。密码子337的突变是p53寡聚化结构域中报道的第二例种系错义突变。